Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MAC-321 · 2 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| MAC-321 | DRUG | - |
Inclusion Criteria: * Recurrence of non-small cell lung cancer after at least 1 prior chemotherapy regimen containing a platinum agent * Recovery from all acute side effects of prior therapies (with the exception of hair loss) * Adequate bone marrow, liver, and kidney function Exclusion Criteria: ...
MAC-321 is an investigational small molecule being studied for the treatment of non-small-cell lung carcinoma and colorectal neoplasms. It was evaluated in Phase 2 clinical trials for these oncology indications.
MAC-321 is being developed by Pfizer, Inc. (NYSE: PFE). The company has conducted clinical trials to evaluate the drug in patients with certain types of cancer.
MAC-321 is in Phase 2 clinical development. It has been studied in completed Phase 2 trials for non-small-cell lung cancer and colorectal cancer, but it is not approved and remains investigational.
MAC-321 has been evaluated in two completed Phase 2 trials: NCT00063219 in non-small-cell lung cancer refractory to platinum-based therapy and NCT00063427 in colorectal cancer. Both trials are completed.
MAC-321 is the primary name used for this investigational drug in clinical trials. No alternative names have been reported in the available clinical trial information.